{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:42Z","timestamp":1783977222088,"version":"3.55.0"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"Objective<\/jats:title>Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition consisting of 2 clinical subsets: nonradiographic axSpA and ankylosing spondylitis, the latter having an estimated prevalence of 0.2% to 1% in Canada. Secukinumab (SEC) received Health Canada approval in 2016 for the treatment of adults with axSpA who have responded inadequately to conventional treatment, and has demonstrated efficacy and safety through extensive clinical trials. However, there is limited evidence on its real-world use in Canada. The objective of this study was to use the Canadian Spondyloarthritis (CanSpA) Research Network to describe real-world retention and effectiveness of SEC in the Canadian axSpA population.<\/jats:p><\/jats:sec>Methods<\/jats:title>This was an observational cohort study of Canadian patients with axSpA aged 18 to 65 years within the CanSpA network who had received treatment with SEC. Patients were indexed on the first date of SEC initiation. Retention and clinical effectiveness were assessed at 12 months postindex. Clinical effectiveness was measured as the proportion in remission and change in disease activity using multiple clinical indices.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 146 patients were included. Overall retention was estimated at 62.9%. Low disease activity (ie, Bath Ankylosing Spondylitis Disease Activity Index < 4) was achieved in 29.2% of patients, and 2% had achieved remission based on the Ankylosing Spondylitis Disease Activity Score. Bath Ankylosing Spondylitis Metrology Index scores improved by more than 60% from baseline to 12 months.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The results of this real-world study of Canadian patients with axSpA, one of the first of its kind, support the effectiveness of SEC for treatment of axSpA. The CanSpA network presents an opportunity to continue building and improving the real-world evidence base for treatment of Canadian patients with spondyloarthritis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220824","type":"journal-article","created":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T13:25:17Z","timestamp":1673789117000},"page":"634-640","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-1422","authenticated-orcid":false,"given":"Robert D.","family":"Inman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-7695","authenticated-orcid":false,"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-5128","authenticated-orcid":false,"given":"Majed","family":"Khraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamiza","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Neish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,1,15]]},"reference":[{"key":"2023061203300622000_50.5.634.1","unstructured":"American College of Rheumatology . Spondyloarthritis [Internet. Accessed August 18, 2022.] Available from: https:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Diseases-Conditions\/Spondyloarthritis"},{"key":"2023061203300622000_50.5.634.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2023061203300622000_50.5.634.3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000475"},{"key":"2023061203300622000_50.5.634.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006634"},{"key":"2023061203300622000_50.5.634.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141000"},{"key":"2023061203300622000_50.5.634.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2023061203300622000_50.5.634.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025"},{"key":"2023061203300622000_50.5.634.8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s10067-020-05433-5","article-title":"Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study","volume":"40","author":"Ganapati","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2023061203300622000_50.5.634.9","unstructured":"American College of Rheumatology . Secukinumab (Cosentyx). [Internet. Accessed August 18, 2022.] Available from: https:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Treatments\/Secukinumab-Cosentyx"},{"key":"2023061203300622000_50.5.634.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2023061203300622000_50.5.634.11","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","article-title":"5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial","volume":"2","author":"Marzo-Ortega","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023061203300622000_50.5.634.12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023061203300622000_50.5.634.13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"2023061203300622000_50.5.634.14","doi-asserted-by":"crossref","first-page":"POS0234","DOI":"10.1136\/annrheumdis-2021-eular.2263","article-title":"Secukinumab retention and safety in patients with active psoriatic arthritis or ankylosing spondylitis: 2 year interim results of the observational SERENA study [abstract]","volume":"80","author":"Kiltz","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023061203300622000_50.5.634.15","unstructured":"Aydin SZ , Inman R , Masetto A , Secukinumab dose escalation for the treatment of ankylosing spondylitis in Canada: retrospective analysis using real world data from the XPOSE patient support program. Paper presented at: CRA & AHPA Annual Scientific Meeting; 2021 February 24; Virtual."},{"key":"2023061203300622000_50.5.634.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21570"},{"key":"2023061203300622000_50.5.634.17","doi-asserted-by":"crossref","unstructured":"Kiltz U , Peterlik D , Winkelmann V , Tony HP. AQUILA study in Germany \u2013 real world adherence and persistence of secukinumab treatment in ankylosing spondylitis and psoriatic arthritis patients \u2013 an interim analysis [abstract]. Ann Rheum Dis 2019;1814-15.","DOI":"10.1136\/annrheumdis-2019-eular.435"},{"key":"2023061203300622000_50.5.634.18","unstructured":"Aydin S , Rahman P , Chan J Real-world effectiveness of secukinumab in the treatment of ankylosing spondylitis in Canada: retrospective analysis using data from the patient support program. Paper presented at: CRA & AHPA Annual Scientific Meeting; 2020 February 26-29; Victoria, Canada."},{"key":"2023061203300622000_50.5.634.19","first-page":"0354","article-title":"How do TNF-alpha-inhibitors in medical history affect patient reported outcomes and retention in ankylosing spondylitis patients treated with secukinumab in real world? \u2013 German observational study [abstract]","volume":"72","author":"Kiltz","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023061203300622000_50.5.634.20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40744-020-00269-6","article-title":"Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies","volume":"8","author":"Baraliakos","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2023061203300622000_50.5.634.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150463"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T10:31:43Z","timestamp":1686565903000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.3899\/jrheum.220824"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220824","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]}}}